- Trials with a EudraCT protocol (1,500)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,500 result(s) found for: Poland syndrome.
Displaying page 1 of 75.
EudraCT Number: 2018-000106-32 | Sponsor Protocol Number: 03-CL-1702 | Start Date*: 2019-06-26 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A Multinational, Multicenter, Masked, Randomized, Parallel Group, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation versus nCPAP alone in Preterm Neonates 26 to 32 We... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005624-26 | Sponsor Protocol Number: 03-CL-1401 | Start Date*: 2016-05-30 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.) | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 26 to 28 Weeks PMA. | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003519-40 | Sponsor Protocol Number: 03-CL-1202 | Start Date*: 2016-02-18 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A MULTINATIONAL, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF LUCINACTANT FOR INHALATION IN PRETERM NEONATES 26 TO 32 WEEKS GESTATIONAL AGE WITH RESPIRATOR... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) IE (Completed) NL (Completed) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002913-16 | Sponsor Protocol Number: 0135-0347 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome caused by Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000162-22 | Sponsor Protocol Number: 112025-002 | Start Date*: 2015-05-04 | |||||||||||
Sponsor Name:Laboratoire HRA Pharma | |||||||||||||
Full Title: Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed b... | |||||||||||||
Medical condition: Treatment of Cushing’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) BE (Completed) ES (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003628-42 | Sponsor Protocol Number: NBK182/1/2022 | Start Date*: 2023-03-24 | |||||||||||
Sponsor Name:Medical University of Gdańsk | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial) | |||||||||||||
Medical condition: Takotsubo syndrome (TTS), also known as apical ballooning syndrome, Takotsubo cardiomyopathy, broken heart syndrome, and stress-induced cardiomyopathy, is a rare condition and accounts for 1–3% of ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004616-12 | Sponsor Protocol Number: CCDZ173X2203 | Start Date*: 2016-05-20 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome | |||||||||||||
Medical condition: Primary Sjögren's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001202-32 | Sponsor Protocol Number: TA799-007 | Start Date*: 2020-11-02 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF) | |||||||||||||
Medical condition: short bowel syndrome and intestinal failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) NO (Completed) BE (Completed) HU (Completed) PL (Completed) SE (Completed) DK (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005502-25 | Sponsor Protocol Number: ZP1848-20110 | Start Date*: 2021-04-11 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients with Short Bowel Syndrome (SBS) Completing the EASE S... | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003135-35 | Sponsor Protocol Number: ECU-aHUS-403 | Start Date*: 2016-06-20 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENT | |||||||||||||
Medical condition: atypical Hemolytic-Uremic Syndrome (aHUS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002840-34 | Sponsor Protocol Number: CLCI699C2X01B | Start Date*: 2018-08-03 | |||||||||||
Sponsor Name:Recordati AG | |||||||||||||
Full Title: An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and ... | |||||||||||||
Medical condition: Cushing's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) FR (Completed) ES (Ongoing) BG (Completed) BE (Completed) NL (Ongoing) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000101-37 | Sponsor Protocol Number: IM128-035 | Start Date*: 2017-04-07 | |||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary ... | |||||||||||||||||||||||||||||||||
Medical condition: subjects with moderate to severe Sjögren's syndrome | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001164-11 | Sponsor Protocol Number: KF7013-03 | Start Date*: 2017-04-24 | ||||||||||||||||
Sponsor Name:Grünenthal GmbH | ||||||||||||||||||
Full Title: Open-label safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS) | ||||||||||||||||||
Medical condition: Complex regional pain syndrome (CRPS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004982-37 | Sponsor Protocol Number: NBK155/1/2020 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:MEDICAL UNIVERSITY OF GDAŃSK | |||||||||||||
Full Title: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome | |||||||||||||
Medical condition: NEPHROTIC SYNDROME | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000665-32 | Sponsor Protocol Number: 80202135SJS2001 | Start Date*: 2021-11-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) PT (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004547-36 | Sponsor Protocol Number: CCD-01534CA1-01 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY ... | |||||||||||||
Medical condition: Mild to moderate respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001516-24 | Sponsor Protocol Number: 20060197 | Start Date*: 2007-08-23 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS) | |||||||||||||
Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) SE (Prohibited by CA) BE (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) CZ (Completed) AT (Completed) SK (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004419-32 | Sponsor Protocol Number: PMS-2018-002 | Start Date*: 2019-10-03 | ||||||||||||||||
Sponsor Name:Pharmascience Inc. | ||||||||||||||||||
Full Title: A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel ... | ||||||||||||||||||
Medical condition: Bile-acid induced diarrhea in adult patients with Short Bowel Syndrome (SBS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002178-17 | Sponsor Protocol Number: LPRI-424/304 | Start Date*: 2021-09-27 | |||||||||||
Sponsor Name:Chemo Research S.L. | |||||||||||||
Full Title: A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-424 (dienogest 2.00 mg / ethinyl estradiol 0.02 mg) in the treatment of polycystic ovary ... | |||||||||||||
Medical condition: Hirsutism related to Polycystic Ovarian Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) CZ (Completed) LT (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001331-31 | Sponsor Protocol Number: ZX008-1900 | Start Date*: 2019-11-07 | ||||||||||||||||
Sponsor Name:Zogenix International Limited | ||||||||||||||||||
Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such a... | ||||||||||||||||||
Medical condition: Dravet syndrome or Lennox-Gastaut syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DK (Completed) FR (Completed) ES (Ongoing) DE (Completed) SE (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
